GREETINGS!

Our thoughts go out to all who are struggling in the intense heat of the summer, which can be tough both physically and mentally. Another thing that impacts mental health? TB treatment! In fact, our Chair-Elect, Dr. Jonathan Stillo, published an article, “Being “Cured” but No Longer Being Yourself: Tuberculosis Sequelae and the Unseen Second Lives of Romanian Tuberculosis Survivors.” About the research, Dr. Stillo said, “So many of the people with TB who I had come to know during their treatment were facing difficulties returning to their lives due to harm from TB disease and its treatment. Hearing loss from injectable antibiotics was especially harmful and resulted in students being unable to finish their degrees, mothers unable to communicate with their families, etc. The worst was that this was harm the health system did not see because these problems were self-diagnosed. I hope this article will bring greater attention to the challenges faced by people who are cured of TB, and I am planning additional research to further document this important issue.” Still more motivation for us to work together to #EndTB!!

DC UPDATE

Keep asking your Members of Congress to co-sponsor the End TB Now Act, H.1776/S.288!! First the good news: the End TB Now Act has passed through the House Foreign Affairs Committee markup with a voice vote and the bill is through both the House and the Senate Committees! Here’s a helpful fact sheet and a press release about the End TB Now Act.

Please continue to ask your Representatives and Senators to co-sponsor this important bi-partisan bill! Special thanks to Senator Bob Menendez (D-NJ), Senator Todd Young (R-Ind.), Rep. Ami Bera (D-CA) and Rep. María Elvira Salazar (R-FL), Rep. Brad Sherman (D-CA), and Brian Fitzpatrick (R-PA) for being the lead sponsors! Call or write your members of Congress to ask they co-sponsor the End TB Now Act today.

Call the Capitol Switchboard at 1-202-224-3121 and ask for your senator/representative or give your state if you do not know their name. When you are connected to an office, ask for the Health Legislative Assistant. If you leave a voicemail message, include your name, phone number, and email so that they can respond.

Sample message: I am a constituent from [your town] and I am calling to urge Sen./Rep._____ to co-sponsor the End Tuberculosis Now Act of 2023. Additionally, the End TB Now Act has passed through the committees, and I am looking to your leadership to bring it to the floor. Would you please ask [Senator Schumer (if your Senator is Democrat)/Senator McConnell (if your Senator is Republican) or if a Representative - Representative Jeffries (if a Democrat)/McCarthy (if a Republican)] to bring this bill to the [House/Senate] floor?

The bill outlines a plan and critical actions to align tuberculosis efforts in the U.S. with international efforts. TB, an airborne infectious disease, is once again the leading global infectious disease killer. TB cases and deaths are rising across the globe. [Add a sentence about why you care about TB elimination.] The End TB Now Act will amplify our ability to end TB as a public health threat. I urge Sen./Rep._____ to cosponsor this very important bill. Thank you for your consideration!

Bonus points for sending this via email as well, which also increases your chance of getting a response!
Stay tuned for the introduction of the domestic companion bill, The Comprehensive TB Elimination Act. We’ll need to get lots of cosponsors for that one too...

ANNOUNCEMENTS

Special section on bedaquiline access

- TB Online - Urgent action necessary for equitable access to bedaquiline in all countries with high burdens of TB, MDR-TB, and TB/HIV
- TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands – Treatment Action Group
- John Green on Twitter: "An open letter to @JNJNews. Stop pursuing the secondary patent of bedaquiline. YOU KNOW that millions of people will be unable to access lifesaving treatment for multidrug-resistant tuberculosis if you extend the patent. YOU KNOW it violates your credo. https://t.co/JArPHWpmv5" / Twitter
- TB Online - Global Drug Facility update on access to bedaquiline
- TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries | Médecins Sans Frontières Access Campaign
- Public investments in the clinical development of bedaquiline | PLOS ONE
- PIH Statement on J&J and Stop TB Deal | Partners In Health
- J&J expands global access to TB drug amid advocacy campaign
- Johnson and Johnson shares licence for tuberculosis drug after novelist’s viral campaign | The Independent

HIGHLIGHTED TB REPORTS/UPDATES

Press Release: Funding Late-Stage Development of M72 TB Vaccine Candidate | Bill & Melinda Gates Foundation

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study - Full Text View - ClinicalTrials.gov

TB Online - Germany issues award to IAVI to support development of the MTBVAC TB vaccine candidate

Read more reports and updates on our website page ‘From TB Wire’!

TB IN THE NEWS

- TB Online - Why hunger is driving thousands to abandon the drugs that keep them alive
- 10 Ways to Make Good on the Promise of Ending Tuberculosis - UN Dispatch
- Tuberculosis is a global emergency, and rich nations should treat it as such - The Hill Times
- Promising tuberculosis vaccine gets US$550-million shot in the arm
- SickKids researchers discover new way to attack treatment-resistant TB infections
- DOH employs use of AI to help detect cases of tuberculosis - YouTube
- DOH to launch shorter treatment for tuberculosis | ABS-CBN News

Read lots more TB news on our website page ‘From TB Wire’!

TB RESOURCES

- 4R Regimen for Latent TB Infection medication tracker and symptom checklist (Ukrainian)
- Medication Tracker: 4 Months of Daily Rifampin (4R) for Latent Tuberculosis (TB) Infection
- Registro de medicación: 4 meses de rifampicina diaria (4R) para la infección de tuberculosis (TB)
- TB Education & Training Network | TB | CDC
- Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note
- Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note
- Standardized package of community-based support services to improve tuberculosis outcomes. A guide for affected community and civil society organizations, national tuberculosis programmes and policy-makers in eastern Europe and central Asia

Updated: CDC TB Skin Test Fact Sheet:

CDC has updated the “What You Need to Know About TB Skin Test” fact sheet. Healthcare providers and TB programs can use this fact sheet to educate people about TB skin testing and the importance of getting tested for TB disease. To download copies in English, please check out the CDC website.

Find more TB resources on our website page ‘TB Resources’!

JOURNAL ARTICLES

- Uniting for Ukraine Tuberculosis Screening Experience, San Francisco, California, USA
- COVID-19 impact on health service- and TB-related practices among private providers in Indonesia
- Operationalising targeted next-generation sequencing for routine diagnosis of drug-resistant TB
- Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis
- SARS-CoV-2 infection and pulmonary tuberculosis in children and adolescents: a case-control study | BMC Infectious Diseases
- The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries | BMJ Global Health
- Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis - The Lancet Global Health
- Global, regional, and national estimates of tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a systematic analysis - The Lancet Public Health

Discover many more peer-reviewed articles on our website page ‘Peer-Reviewed Publications’!
COURSES/WORKSHOPS

The Association of Public Health Laboratories (APHL) and the Centers for Disease Control and Prevention (CDC) collaborated to develop an online course, “Understanding TB Laboratory Testing for Public Health Nurses” to help TB nurses and clinicians learn about TB laboratory testing best practices.

The course will aid in communicating effectively and timely with the patient, clinician, and laboratory. To learn more visit APHL.

End TB Course Series

Prevent Tuberculosis: Management of TB Infection, Part II

EVENTS, MEETINGS, & CONFERENCES

ATS 2023 Scientific Symposium - The UN High Level Meeting on TB 2023: A chance to beat this particular pandemic
Chairs: David Lewinsohn and Jess Potter. Talks:
1. Living with TB, Samara Barnes & Kelly Holland
2. Beyond cure – Living with the long-term effects, Jess Potter
3. UN High-Level Meeting on TB, Matt Oliver
4. Policy into practice to make a difference, Kate O’Brien

The Advisory Council for the Elimination of Tuberculosis (ACET) held their bi-annual meeting on June 20-21, 2023. A variety of topics were discussed, including recommendations for policies, strategies, objectives, and priorities to eliminate TB.

Recording: The ABC for a TB Activist: 1/4/6×24 Campaign and Supportive Diagnostics:

APHA Annual Meeting and Expo Registration: APHA 2023 is the premier public health event of the year. Learn from leading experts, build leadership skills and knowledge and connect with peers from around the globe, all with the choice and flexibility to select the best format for you.

Stop TB USA: Where we unite to #EndTB!

Invite a friend to sign up to receive the TB Wire and be a part of Stop TB USA!

Consider donating: Make a check out to NTCA (our fiscal home) with “Stop TB USA donation” in the memo line.

Send to PO Box 260288, Atlanta, GA 31126

Stop TB USA
stoptbusa.org
leadership@stoptbusa.org
2452 Spring Rd., SE Smyrna GA 30080 USA